Dự đoán độc tính tủy xương do thuốc gây ra bằng phương pháp Naïve Bayes

Parent-Massin D, Hymery N, Sibiril Y (2010) Stem cells in myelotoxicity. Toxicology 267:112–117. doi:10.1016/j.tox.2009.10.031 Gribaldo L, Casati S, Figliuzzi L, Marafante E (1998) In vitro myelotoxicity of environmental contaminants. Environ Toxicol Pharmacol 6:135–141. doi:10.1016/S1382-6689(98)00029-5 De Jager R, Cheverton P, Tamanoi K, Coyle J, Ducharme M, Sakamoto N, Satomi M, Suzuki M (2000) DX-8951f: summary of phase I clinical trials. Ann N Y Acad Sci 922:260–273. doi:10.1111/j.1749-6632.2000.tb07044.x Gribaldo L, Malerba I, Collotta A, Casati S, Pessina A (2000) Inhibition of CFU-E/BFU-E by 3-azido-3-deoxythymidine, chlorpropamide, and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures. Toxicol Sci 58:96–101. doi:10.1093/toxsci/58.1.96 Gisbert JP, Gomollón F (2008) Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103:1783–1800. doi:10.1111/j.1572-0241.2008.01848.x Masubuchi N, May RD, Atsumi R (2004) A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony forming unit granulocyte/macrophage assay. Clin Cancer Res 10:6722–6731. doi:10.1158/1078-0432.CCR-04-0721 Holt DE, Andrews CM, Payne JP, Williams TC, Turton JA (1998) The myelotoxicity of chloramphenicol: in vitro and in vivo studies: II: in vivo myelotoxicity in the B6C3F1 mouse. Hum Exp Toxicol 17:8–17. doi:10.1177/096032719801700102 Sanpera N, Masot N, Janer M, Romeo C, De Pedro R (2002) Oestrogen-induced bone marrow aplasia in a dog with a Sertoli cell tumour. J Small Anim Pract 43:365–369. doi:10.1111/j.1748-5827.2002.tb00087.x Parchment RE, Huang M, Erickson-Miller CL (1993) Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21:241–250. doi:10.1177/019262339302100217 Le Dréan G, Auffret M, Batina P, Arnold F, Sibiril Y, Arzur D, Parent-Massin D (2005) Myelotoxicity of trichothecenes and apoptosis: an in vitro study on human cord blood CD34\(^+\) hematopoietic progenitor. Toxicol In Vitro 19:1015–1024. doi:10.1016/j.tiv.2005.03.017 Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, Croera C, Gagliardi G, Foti P, Parchment R, Parent-Massin D, Schoeters G, Sibiril Y, Van Den Heuvel R, Gribaldo L (2003) Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355–367. doi:10.1093/toxsci/kfg188 Rio B, Lautraite S, Parent-Massin D (1997) In vitro toxicity of trichothecenes on human erythroblastic progenitors. Hum Exp Toxicol 16:673–679. doi:10.1177/096032719701601108 Stephenson J, Axelrad AA, Mc Leod DL, Shreeve MM (1971) Induction of colonies of hemoglobin-synthesizing cells by erythropoietin. Proc Natl Acad Sci USA 68:1542–1546. doi:10.1073/pnas.68.7.1542 Friedenstein AJ, Chailakhyan RK, Laliykina KS (1970) The development of fibroblasts colonies in monolayer cultures of guinea pig bone marrow and spleen. Cell Tissue Kinet 3:393–403. doi:10.1111/j.1365-2184.1970.tb00347.x Naughton BA, Sibanda D, Azar L, San Roman J (1992) Differential effects of drugs upon hematopoiesis can be assessed in long-term bone marrow culture established on nylon screens. Proc Soc Exp Biol Med 199:481–490. doi:10.3181/00379727-199-43384 Dickins M, Modi S (2002) Importance of predictive ADME simulations. Drug Discov Today 7:755–756. doi:10.1016/j.drudis.2011.10.022 Grime KH, Barton P, McGinnity DF (2013) Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. Mol Pharm 10:1191–1206. doi:10.1021/mp300476z Kimber I, Humphris C, Westmoreland C, Alepee N, Dal Negro G, Manou I (2011) Computational chemistry, systems biology and toxicology. Harnessing the chemistry of life: revolutionizing toxicology. A commentary. J Appl Toxicol 31:206–209. doi:10.1002/jat.1666 Modi S, Hughes M, Garrow A, White A (2012) The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries. Drug Discov Today 17:135–142. doi:10.1016/j.drudis.2011.10.022 Modi S (2004) Positioning ADMET in silico tools in drug discovery. Drug Discov Today 9:14–15. doi:10.1016/S1359-6446(04)02956-3 Vedani A, Smiesko M (2009) In silico toxicology in drug discovery—concepts based on three-dimensional models. Altern Lab Anim 37:477–496. doi:10.1016/j.taap.2009.08.022 Ekins S, Williams AJ, Xu JJ (2010) A predictive ligand-based bayesian model for human drug-induced liver injury. Drug Metab Dispos 38:2302–2308. doi:10.1124/dmd.110.035113 Ekins S (2014) Progress in computational toxicology. J Pharm Toxicol Methods 69:115–140. doi:10.1016/j.vascn.2013.12.003 Hu X, Yan A (2012) In silico models to discriminate compounds inducing and noninducing toxic myopathy. Mol Inf 31:27–39. doi:10.1002/minf.201100067 Zhang H, Li W, Xie Y, Wang WJ, Li LL, Yang SY (2011) Rapid and accurate assessment of seizure liability of drugs by using an optimal support vector machine method. Toxicol In vitro 25:1848–1854. doi:10.1016/j.tiv.2011.05.015 Zhang H, Chen QY, Xiang ML, Ma CY, Huang Q, Yang SY (2009) In silico prediction of mitochondrial toxicity by using GA-CG-SVM approach. Toxicol In Vitro 23:134–140. doi:10.1016/j.artmed.2008.07.001 Box GEP, Tiao CC (1973) Bayesian inference in statistical analysis. Addison-Wesley, Reading Berger JO (1985) Statistical decision theory and bayesian analysis. Springer, New York Langdon SR, Mulgrew J, Paolini GV, van Hoorn WP (2010) Pre-dicting cytotoxicity from heterogeneous data sources with Bayesian learning. J Cheminform 2:11–29. doi:10.1186/1758-2946-2-11 Di-wu L, Li LL, Wang WJ, Xie HZ, Yang J, Zhang CH, Huang Q, Zhong L, Feng S, Yang SY (2012) Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking. J Mol Graph Model 36:42–47. doi:10.1016/j.jmgm.2012.03.004 Yang Y, Zhang W, Cheng JG, Tang Y, Peng YQ, Li Z (2013) Pharmacophore, 3D-QSAR, and bayesian model analysis for ligands binding at the benzodiazepine site of GABAA receptors: the key roles of amino group and hydrophobic sites. Chem Biol Drug Des 81:583–590. doi:10.1111/cbdd.12100 Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C, Ekins S (2010) Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol 23:664–676. doi:10.1021/tx900417f Rogers D, Brown RD, Hahn M (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10:682–686. doi:10.1021/tx900417f Yang SY, Huang Q, Li LL, Ma CY, Zhang H, Bai R, Teng QZ, Xiang ML, Wei YQ (2009) An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs. Artif Intell Med 46:155–163. doi:10.1016/j.artmed.2008.07.001 Li LK, Shao S, Yiu KFC (2013) A new optimization algorithm for single hidden layer feedforward neural networks. Appl Soft Comput 13:2857–2862. doi:10.1016/j.asoc.2012.04.034 Crivori E, Pennella G, Magistrelli M, Grossi P, Giusti AM (2011) Predicting myelosuppression of drugs from in silico models. J Chem Inf Model 51:434–445. doi:10.1021/ci1003834